UNH - Bragar Eagel & Squire P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Equinix Harbor Diversified Altimmune and UnitedHealth and Encourages Investors to Contact the Firm | Benzinga
NEW YORK, May 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Equinix (NASDAQ:EQIX), Harbor Diversified, Inc. (OTC:HRBR), Altimmune, Inc. (NASDAQ:ALT), and UnitedHealth Group Incorporated (NYSE:UNH). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Equinix (NASDAQ:EQIX)
Class Period: May 3, 2019 - March 24, 2024
Lead Plaintiff Deadline: July 1, 2024
According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Equinix manipulated its financials to reduce operational expenses and boost Adjusted Funds From Operations ("AFFO"); (2) Equinix oversold power capacity and did not warn of the risks associated with this practice; (3) Equinix lacked adequate internal controls; and (4) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
For more information on the Equinix class action go to: https://bespc.com/cases/EQIX
Harbor Diversified, Inc. (OTC:HRBR)
Class Period: May 10, 2022 - March 29, 2024
Lead Plaintiff Deadline: July 8, 2024
According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Harbor Diversified's financial statements from May 9, 2022 to the present were misstated due to improper revenue recognition; (2) Harbor Diversified lacked adequate internal controls; and (3) as a result, defendants' statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times.
For more information on the Harbor Diversified class action go to: https://bespc.com/cases/HRBR
Altimmune, Inc. (NASDAQ:ALT)
Class Period: December 1, 2023 - April 26, 2024
Lead Plaintiff Deadline: July 5, 2024
Altimmune is a clinical stage biopharmaceutical company that focuses on developing treatments for obesity and liver diseases. The Company's lead product candidate is pemvidutide, a glucagon-like peptide-1 ("GLP-1") agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis ("MASH"). GLP-1 agonists are medications that help lower blood sugar levels and promote weight loss.
On November 30, 2023, Altimmune announced topline results from its 48-week MOMENTUM Phase 2 trial evaluating pemvidutide for the treatment of obesity (the "MOMENTUM Trial"). According to the Company, at week 48, subjects receiving pemvidutide achieved mean weight losses of 10.3%, 11.2%, 15.6% and 2.2% at the 1.2 mg, 1.8 mg, and 2.4 mg doses and placebo, respectively, with a near-linear trajectory of ...